Literature DB >> 16639080

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.

C Chabalier1, C Lamare, C Racca, M Privat, A Valette, F Larminat.   

Abstract

BRCA1 germline mutations predispose women to early onset, familial breast and ovarian cancer. BRCA1 has been recently implicated in the cellular response to agents that disrupt the mitotic spindle. In this report, we studied BRCA1 contribution to paclitaxel response in MCF-7 breast cancer cells. We show that MCF-7 cells transfected with BRCA1 siRNA display a significant increase in resistance to paclitaxel compared with the control cells. We next demonstrate that downregulation of BRCA1 reduces the mitotic index and triggers premature cyclin B1 degradation and decrease in Cdk1 activity following paclitaxel treatment, suggesting that BRCA1 downregulation results in precocious inactivation of the spindle checkpoint. These findings were confirmed by showing that BRCA1 downregulation induces premature sister-chromatids separation in MCF-7 cells following spindle damage. Furthermore, we show that BRCA1 up-regulates the expression of the protein kinase BubR1, essential component of the functional spindle checkpoint, whose downregulation is known to result in paclitaxel resistance in MCF-7 cells. Altogether, our findings support the notion that downregulation of BRCA1 expression mediates paclitaxel resistance through premature inactivation of spindle checkpoint in MCF-7 breast cancer cells. They link BRCA1 to the mitotic checkpoint that plays an essential role in the maintenance of chromosomal stability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16639080     DOI: 10.4161/cc.5.9.2726

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  50 in total

Review 1.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

Review 2.  Triple-negative breast cancer.

Authors:  Rupert Bartsch; Reinhard Ziebermayr; Christoph C Zielinski; Guenther G Steger
Journal:  Wien Med Wochenschr       Date:  2010-04

3.  Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.

Authors:  Anil Belur Nagaraj; Olga Kovalenko; Rita Avelar; Peronne Joseph; Annalyn Brown; Arshia Surti; Sandra Mantilla; Analisa DiFeo
Journal:  Clin Cancer Res       Date:  2018-04-13       Impact factor: 12.531

Review 4.  Management of hereditary breast and ovarian cancer.

Authors:  Hideko Yamauchi; Junko Takei
Journal:  Int J Clin Oncol       Date:  2017-11-28       Impact factor: 3.402

5.  Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.

Authors:  David J Gallagher; Angel M Cronin; Matthew I Milowsky; Michael J Morris; Jasmine Bhatia; Peter T Scardino; James A Eastham; Kenneth Offit; Mark E Robson
Journal:  BJU Int       Date:  2011-07-14       Impact factor: 5.588

Review 6.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

7.  The spindle assembly checkpoint: More than just keeping track of the spindle.

Authors:  Katherine S Lawrence; JoAnne Engebrecht
Journal:  Trends Cell Mol Biol       Date:  2015

8.  In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

Authors:  G Metro; Z Zheng; A Fabi; M Schell; B Antoniani; M Mottolese; A N Monteiro; P Vici; S Lara Rivera; D Boulware; F Cognetti; G Bepler
Journal:  Cancer Invest       Date:  2010-02       Impact factor: 2.176

Review 9.  Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Authors:  J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

10.  The closely related RNA helicases, UAP56 and URH49, preferentially form distinct mRNA export machineries and coordinately regulate mitotic progression.

Authors:  Tomohiro Yamazaki; Naoko Fujiwara; Hiroko Yukinaga; Miki Ebisuya; Takuya Shiki; Tomoya Kurihara; Noriyuki Kioka; Taiho Kambe; Masaya Nagao; Eisuke Nishida; Seiji Masuda
Journal:  Mol Biol Cell       Date:  2010-06-23       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.